Tumor suppressor gene p16 is a cyclin-dependent kinase inhibitor and an important negative cell cycle regulator. The inactivation of p16 appears to be a common event in prostate cancer. Replacement of p16 inhibits prostate tumor cell growth, but the mechanism is not known. Human prostate cancer cell lines PPC-1, which has an inactivated p16, and DU145, which has a nonfunctional retinoblastoma Rb protein (pRb), were used to determine the possible mechanism of p16 mediated growth inhibition. PPC-1 cells treated with 5-aza-2'-deoxycytidine (5-aza-dC), a demethylating agent, induced p16 expression, inhibited cell growth, and induced senescence. Similarly, PPC-1 cells transduced by an adenoviral vector containing the p16 gene (AdRSVp16) produced a p16 protein that suppressed cellular proliferation and induced senescence. Co-staining of AdRSVp16-transduced PPC-1 cells by p16 immunohistochemistry and by b-galactosidase substrate X-gal showed that the morphologically enlarged cells expressed both p16 and senescence-associated b-galactosidase. In contrast, AdRSVp16 did not induce senescence in DU145 cells, but did inhibit its growth. However, when wild-type pRb was introduced in DU145 cells, AdRSVp16 was able to induce senescence. Thus, the mechanism by which p16 suppressed prostate cancer was dependent on the pRb functional status of cells whereby p16 caused pRb + cells to undergo inhibition by senescence, whereas pRb 7 cells were also inhibited, but not by senescence.
Introduction
The cyclin dependent kinase inhibitor (CDK1) p16, also known as MTS1, INK4A and CDKN2, is an important negative cell cycle regulator (Shapiro and Rollins, 1996) . Loss of p16 contributes to malignant phenotype (Liggett and Sidransky, 1998) . Cyclin dependent kinases (CDKs) are essential phosphorylating enzymes in association with other proteins called cyclins whose activity are tightly regulated by protein phosphorylation (Norbury and Nurse, 1992; Sherr et al., 1993; Bates et al., 1994) . The activation of CDKcyclin complexes is responsible for the orderly transition of the cell through the cell cycle; the CDKcyclin complex phosphorylates pRb protein which promotes cell cycle progression. In contrast, CDK inhibitors, like p16, prevent activation of CDK-cyclin complexes (CDK4/cyclin D) by sequestering CDK4 component from the CDK4/cyclin D complex. (Itoh et al., 1997) As a consequence, the underphosphorylated pRb remains in its growth suppressive form arresting cell cycle transition (Serrano et al., 1993; Guan et al., 1994) .
Inactivation of p16 tumor suppressor gene has emerged as one of the most common carcinogenetic events for a wide range of tumor types (Mori et al., 1994; Nobori et al., 1994; Okamoto et al., 1994; Liu et al., 1995; Orlew et al., 1995; Smith-Sorenson and Hovig, 1995; Takeuchi et al., 1995; Washimi et al., 1995; Xiao et al., 1995a; Geradts and Wilson, 1996; Talve et al., 1997) . Mechanisms that have been reported to alter p16 expression in oncogenesis include DNA mutations (Hussussian et al., 1994) , homozygous loss of p16 gene, (Caldas et al., 1994; Jen et al., 1994; Cairns et al., 1995; Hatta et al., 1995; Xiao et al., 1995b; Li et al., 1995; Chen et al., 1996) , and hypermethylation of promoter region (Mao et al., 1995; Herman et al., 1996) . Hypermethylation of the p16 promoter has been observed in the majority of prostate cancer cell lines including TSU-Pr (Jarrard et al., 1997) , PC3 (Itoh et al., 1997; Jarrard et al., 1997) , and PPC-1 cells (Jarrard et al., 1997) . The mechanism of p16 inactivation in DU145 cell line, however, is a missense mutation in coding sequence of p16 gene (Itoh et al., 1997) .
Restoring p16 protein expression suppresses the growth of a variety of tumor types (Serrano et al., 1993 Arap et al., 1995; Fueyo et al., 1996; Quesnel et al., 1996; Schrump et al., 1996; Stone et al., 1996; Gotoh et al., 1997; Hama et al., 1997; Sandig et al., 1997) . One mechanistic clue is that overexpression of p16 results in block of cell division in a pRbdependent manner (Guan et al., 1994; Lukas et al., 1995) . Previous studies have shown that replacement of p16 protein expression inhibited the growth of prostate cancer cells in vitro and in vivo . Though several hypothetical schemes for p16/CDK4-cyclin D/pRb regulation pathways have been suggested (Kratzke et al., 1995; Foulkes et al., 1997; Haas et al., 1997) , the actual mechanism by which p16 inhibits cell growth remains to be elucidated. In this current study, p16 inhibited prostate cancer cell growth and the method of growth suppression was dependent on the pRb status of cells. If pRb was intact, p16 induced senescence; however, if pRb was absent or nonfunctional, p16 still inhibited growth, but not by senescence.
Results
Demethylation inhibited cell growth, stimulated endogenous p16 expression, and induced senescence Prostate cancer cell line, PPC-1, does not express endogenous p16 protein because of hypermethylation of the p16 promoter (Itoh et al., 1997) . Treatment of PPC-1 cells by 5-aza-dC, a demethylating agent (Vogt et al., 1998) should induce expression of endogenous p16. Indeed, p16 expression was stimulated following after 5-aza-dC treatment ( Figure 1a ) which was associated with growth inhibition (Figure 1b) . Phenotypically, the 5-aza-dC treated cells became enlarged and¯attened with prominent lipofuscin granules (Figure 2b ), a known marker for senescence (Vogt et al., 1998) . In contrast, control cells reached con¯uence and exhibited the typical PPC-1 cell morphology (Figure 2a ). To determine whether 5-azadC treated cells indeed became senescent, a senescenceassociated biomarker, the endogenous b-galactosidase at pH 6.0 (Dimri et al., 1995) , was assessed by X-gal staining. The 5-aza-dC treated enlarged cells had the characteristic blue staining associated with senescence ( Figure 2b ).
AdRSVp16 transduced PPC-1 cells expressed p16, inhibited cellular growth, and induced senescence To determine whether 5-aza-dC treated cells became senescent because of the increased levels of p16, PPC-1 cells were transduced by adenoviral vector containing wild-type p16 gene (AdRSVp16). The mRNA for p16 was detectable in PPC-1 cells as early as 24 h after AdRSVp16 transduction, and the level of p16 mRNA increased and peaked by 72 h after viral transduction ( Figure 3 and Table 1 ). High level of p16 protein expression was also detected in culture cells by Western blotting during the same time period (data not shown). As shown in Figure 4 , expression of exogenous wildtype p16 signi®cantly suppressed PPC-1 cell growth (AdRSVp16 treated cells were inhibited by 95% relative to control PPC-1 cells). The control virus AdRSV2C9 (an adenovirus carrying an unrelated gene) treated PPC-1 cells had only minor growth inhibition probably attributed to the nonspeci®c eects of adenoviral proteins. The AdRSVp16 treated PPC-1 cells had the same morphologic changes exhibited by the 5-aza-dC treated PPC-1 cells. The AdRSVp16-transduced cells were larger and¯atter than control cells ( Figure 5 : compare a or b with c). To determine Figure 5d ,e). In contrast, control cells had neither p16 immunostaining nor positive X-gal staining (Figure 5f ). In summary, both 5-aza-dC and AdRSVp16 resulted in p16 expression, growth inhibition, morphological changes, and senescence in PPC-1 cells. These results are consistent with the notion that the mechanism of p16 mediated growth inhibition was by the induction of senescence in PPC-1 cells.
Induction of senescence by p16 required wild-type pRb
Rb has been proposed as a downstream component of the p16 pathway (Lukas et al., 1995; Kratzke et al., 1996; Foulkes et al., 1997; Haas et al., 1997) . DU145 human prostate cancer cell line which has a truncated, nonfunctional pRb (Bookstein et al., 1990; Sarkar et al., 1992; Steiner and Anthony et al., 1996) , was used to determine whether pRb was involved in p16-induced senescence. PPC-1 cells which expressed a wild-type pRb cells became senescent and had an enlarged, attened morphological change following AdRSVp16 transduction (Figure 5a ± c) . In contrast, DU145 cells which lacked a functional pRb did not demonstrate evidence of senescence following AdRSVp16 transduction (Figure 6c ). Moreover, AdRSVp16-treated DU145 cells had no apparent cell size change though with a reduced cell number compared to untreated control cells or control virus treated cells (compare Figure 6c with a or b).
Two DU145 sublines, DUC-1 and DUC-2 (Banerjee et al., 1992) , which were stably transfected with wildtype pRb expression vector, were used to investigate whether wild-type pRb protein was required for the p16-induced senescence. If wild-type Rb protein is required for the p16-induced senescence, then treatment of DUC-1 and DUC-2 cells with AdRSVp16 should induce senescence. Total RNA and protein extracts from DU145, DUC-1 and DUC-2 cells were analysed for Rb expression. RT ± PCR using primers spanning at nucleotide positions from 2054 and 2490 of Rb cDNA gene were used to distinguish mutant Rb (resulting in a 332 bp RT ± PCR product) from wildtype Rb (resulting in a 437 bp RT ± PCR product) (Bookstein et al., 1990) . As shown in Figure 7 , the RT ± PCR result con®rmed that DU145 had a mutated truncated Rb gene expression and that the two wildtype Rb-replaced sublines DUC-1 and DUC-2 expressed wild-type Rb mRNA and low levels of endogenous mutant Rb mRNA. Western blot analysis using anti-pRb showed a 110 Kd pRb protein in DUC-1, DUC-2, and control PPC-1 cells, but no detectable pRb in DU145 cells (Figure 8 ). Interestingly, there were reports showing that smaller, truncated 97 kd Rb protein in DU145 (Bookstein et al., 1990; Steiner and Anthony, 1996) . One explanation is that the anti-pRb antibody we used may not recognize the truncated form (97 Kd) of pRb protein. PPC-1 cells were untreated or treated with AdRSVp16 at moi=200. Total RNA were extracted at various times and subjected to Northern blot hybridization with 32 P-labeled probes of p16, c-Myc, and b-actin cDNA respectively. The density of each signal band was scanned by a densitometer and the ratios of c-Myc and p16 versus housekeeping gene b-actin were shown To determine whether p16 expression had dierential growth eects on the parental DU145 cells compared to the wild-type Rb-expressing subclones DUC-1 and DUC-2, all three sublines were transduced by AdRSVp16. Cellular proliferation was assessed by counting cell number at day 6 after viral infection. As shown in Figure 9 , following AdRSVp16 transfection, all three sublines demonstrated growth inhibition relative to controls: DU145 cells (58%), DUC-1 (79%) and DUC-2 (68%). Thus, p16 suppressed prostate cancer cell growth in both mutant (pRb 7 ) and wildtype pRb (pRb + ) prostate cancer cells.
Treatment of DU145 sublines by 5-aza-dC increases endogenous mutant p16 expression but does not induce senescence
To con®rm that the introduction of wild-type p16 but not 5-aza-dC itself induced senescence in DU145 sublines, DU145, DUC-1, and DUC-2 cells were treated with 5-aza-dC. As the mechanism for defective p16 is a missence protein, and not a consequence of hypermethylation of the p16 promoter, there was little change in mutant p16 mRNA levels ( Figure 10 ). Moreover, senescence was not observed in either parental DU145 cells or DUC-1 and DUC-2 subclones following 5-aza-dC (data not shown). Thus, 5-aza-dC induced senescence appears to be mediated by wildtype p16 as shown in PPC-1 cells. To generalize the observation that p16 inhibits growth by both pRb dependent and independent pathways, and pRb is required for induction of senescence by p16, several other prostate cancer cell lines with dierent endogenous p16 and pRb status were used for the similar studies, including p16 (Table 2) , these results consistently demonstrated that p16 suppresses prostate cancer growth in both pRb + and pRb 7 cells, but p16-induced senescence is pRb dependent.
Effect of p16 on cell cycle regulation
There have been reports that p16 blocks cell cycle at G 0 /G 1 phase (Mobley et al., 1998; Wolf et al., 1999) . To determine whether AdRSVp16 blocks cell cycle at G 0 /G 1 phase in our study and whether pRb status would aect the cell cycle block by p16, PPC-1 and DU145 cell lines were transduced with AdRSVp16 and cell cycle distribution was followed by¯ow cytometry at dierent time points. As shown in Table 3 , AdRSVp16 eectively arrested PPC-1 cells at G 0 /G 1 phase, this eect was immediate as it has already reached 85.7% cell population at G 0 /G 1 on day 2 post viral transduction, which was consistent with the observations of another group that G 0 /G 1 arrest of cells occurred beginning 24 h after introduction of p16 gene (Wolf et al., 1999) . In contrast, untreated control or control virus treated cells underwent similar, unblocked cell cycle. The longer incubation (day 6, Figure 6 p16-induced senescence required a wild-type Rb protein. DU145 (a ± c) and its Rb-expressing stable transfectant cell lines DUC-1 (d ± f) and DUC-2 (g ± i) were either untreated (a, d and g) or transduced by control adenovirus AdRSV2C9 (b, e and h) or AdRSVp16 (c, f and i) at moi=100 for 7 days. Shown are X-gal staining for senescent cells. All the photos are at the same magni®cation (original 666) Figure 7 RT ± PCR of Rb gene in DU145 and its wild-type Rbexpressing sublines. Reverse transcriptase reaction using total RNA isolated from cells was carried out. An aliquot of the RT mixture was subsequently used for the PCR reaction. The primers speci®c to Rb gene exon 21 which resulted a 332 bp RT ± PCR product for truncated Rb gene and a 437 bp RT ± PCR product for wild-type Rb gene. To ensure the quality of total RNA samples, the same RT mixture mentioned above was used for PCR of housekeeper gene b-actin which resulted a 314 bp PCR product day 9 posttransduction) of the cells showed that while AdRSVp16 treated PPC-1 cells were kept arresting at G 0 /G 1 phase, untreated control or control virus treated cells had a recycled cell cycle pattern (data not shown). Interestingly, the pRb 7 cell line DU145 showed no G 0 / G 1 arrest compared to untreated control and control virus treated cells (Table 3) . Whether the requirement of wild-type pRb for senescence also plays a role for the G 0 /G 1 arrest needs to be further investigated.
Discussion
CDKI p16 has been shown to suppress cellular proliferation. The mechanism by which p16 inhibits cell growth, however, remains to be elucidated. There is much evidence to suggest that p16 may suppress cellular proliferation by inducing senescence. One observation by Hara et al. (1996) showed that p16 protein levels in primary proliferating human ®bro-blasts are very low, but become high as ®broblasts become senescent. Embryo ®broblasts from p16 knockout transgenic mice also exhibit markedly delayed senescence suggesting that p16 is critical for induction of senescence (Serrano et al., 1996) . Conversely, loss of p16 expression has been linked to the immortal phenotype in several human keratinocyte cell lines (Loughran et al., 1996) . Similarly, senescent human uroepithelial cells have elevated p16 levels, whereas immortal E6 transformed cells have undetectable p16 protein (Rezniko et al., 1996) . Other indirect p16 studies have focused on demethylation that has been shown to play a role in cell aging. The 5-methyl cytosine content of DNA in primary culture cells in humans and rodents decreased with their duration in culture (Wilson and Jones, 1983) . A demethylating agent 5-aza-dC shortened the life span of normal human ®broblasts (Holliday, 1986; Fairweather et al., 1987) . Demethylation by 5-aza-dC increased both p16 and p21 expression, and senescence concurrently in human ®broblasts (Vogt et al., 1998) . Thus, treatment of 5-aza-dC increases p16 expression which is associated with senescence. More directly, introduction of the p16 gene in malignant glioma cells arrested cell growth, increased cell size and induced senescence (Fueyo et al., 1996; Uhrbom et al., 1997) . Transduction of immortal human ®broblast by retrovirus containing p16 also directly induced senescence (Vogt et al., 1998) .
One emerging role of p16 is the mediation of senescence. Several studies showed p16 induces senescence (Fueyo et al., 1996; Palmero et al., 1997; Uhrbom et al., 1997; Vogt et al., 1998) and pRb may be required in the p16 mediated growth inhibition (Guan et al., 1994; Lukas et al., 1995; Craig et al., 1998) . However, there is no direct evidence to show that pRb is required for p16-induced senescence. In this study our group demonstrated directly for the ®rst time that pRb is required in p16 mediated senescence in prostate cancer cells. This current study utilized a well established human prostate cancer cell line PPC-1, which has inactivation of p16 but a wild-type pRb, and another human prostate cancer cell line DU145 which has a nonfunctional p16 (missense mutation) and a Figure 8 pRb expression in DU145 and its wild-type Rbexpressing sublines. Western blot of protein extracts from DU145, DUC-1 and DUC-2 cells were immunoblotted with anti-pRb antibody. pRb + cell line PPC-1 was used as a positive control. The same blot was incubated with anti-actin antibody for the demonstration of equal loading of protein (data not shown) Figure 9 Eect of AdRSVp16 on growth of DU145, DUC-1, and DUC-2 sublines. Cells were transduced by AdRSVp16 or control virus (AdRSV2C9) at moi=100 and incubated for 6 days. Counts were performed in duplicate Figure 10 Eect of p16 expression by demethylating agent 5-aza-dC in DU145, DUC-1, and DUC-2 sublines. Shown is a Northern blot of total RNA from DU145, DUC-1 and DUC-2 cells treated with or without 1 mM 5-aza-dC for indicated days. Arrows indicate mRNA of p16 or internal control b-actin p16 suppresses prostate cancer MS Steiner et al nonfunctional pRb. In addition, two DU145 sublines that had wild-type Rb restored were investigated to determine the mechanisms of p16 action. Expression of wild-type p16 was induced in PPC-1 cells either by transduction with AdRSVp16 or by treatment with 5-aza-dC. Elevated p16 levels resulted in growth suppression and the induction of senescence. In contrast, induction of p16 expression in pRb 7 DU145 cells caused growth suppression, but the mechanism did not appear to be by senescence. DU145 subclones, DUC-1, and DUC-2 that have restored wild-type pRb were not only growth suppressed following treatment by AdRSVp16, but also underwent senescence.
These data suggest that p16 may inhibit cellular growth of prostate cancer by either pRb dependent and pRb independent mechanisms. The suppression of pRb + prostate cancer cellular growth appears to be through the induction of senescence. However, pRb 7 prostate cells are still growth inhibited, but evidently by pRb independent mechanisms. Thus, p16 is able to suppress prostate cancer growth regardless of pRb status.
To explore the other growth inhibitory pathway by p16 (the pathway in pRb 7 cells or the one in addition to senescence in pRb + cells), several related cellular components including c-Myc, CDK4, cyclin D, p53, TGFb1 and bcl-2 were screened before and after AdRSVp16 transduction in DU145 and PPC-1 cells. We did not observe signi®cant changes of expression at mRNA levels for CDK4, cyclin D, p53, TGFb1 and bcl-2 in both DU145 and PPC-1 cells (data not shown). In the case of PPC-1 cells, treatment of 5-aza-dC to induce endogenous p16 was also included. As with the results from AdRSVp16 transduction, we did not observe signi®cant changes at mRNA levels for these components after 5-aza-dC treatment (data not shown). However, there was a minor decrease of c-Myc mRNA expression at 24 h after AdRSVp16 transduction, followed by a steady increase of c-Myc mRNA expression up to 72 h after AdRSVp16 transduction in PPC-1 cells (Figure 1 and Table 1 ). Similar results were also observed in DU145 cells (data not shown). These results suggest that c-Myc expression was upregulated by p16. c-Myc is considered as a proapoptosis gene and it downregulates bcl-2 expression (Steiner et al., 1998) . The increased expression of c-Myc by AdRSVp16 transduction implies that p16 may induce apoptosis in addition to senescence. Moreover, combined overexpression of p16 and p53, but not p53 on its own, induces ecient apoptotic death in the majority of tumor cells (Sandig et al., 1997) . In addition, adenovirus expressing p16 inhibits ovarian cancer cell growth and causes apoptosis (Wolf et al., 1999) . These studies imply that p16 has a role in apoptosis. However, we did not detect any apoptosis by DNA fragmentation assay in both PPC-1 cells and DU145 cells after AdRSVp16 transduction (data not shown). Though more sensitive apoptosis assays such as TUNEL and Comet assays are needed to conclude whether apoptosis is another pathway in p16-mediated growth inhibition, we conclude that senescence is not involved in pRb 7 cells by p16 action. Another possible mechanism of p16-mediated, pRb independent growth inhibition is that p16 may involve a G 2 arrest in cell cycle in pRb 7 cells. AdRSVp16-treated DU145 cells had a smaller population in G 0 /G 1 phase (21.7 and 46.9% on day 2 and day 4 posttransduction, respectively) compared to untreated control (51.9 and 69% on day 2 and day 4 posttransduction, respectively) ( Table 3 ). In contrast, AdRSVp16-treated DU145 cells had a 44.3 and 29.7% of G 2 population on day 2 and day 4 posttransduction, respectively, versus 16 and 16.4% of G 2 population in untreated control (data not shown), implying that p16 may have a G 2 arrest in pRb 7 cells, in contrast to that a G 0 /G 1 arrest in pRb + cells. Finally, there could be an unidenti®ed mechanism by which p16 inhibits cell growth in pRb 7 cells.
Materials and methods

Cell culture and medium
Dulbecco's modi®ed Eagle's medium (D-MEM) and RPMI-1640 medium were purchased from Gibco BRL (Gaithersburg, MD, USA) and fetal bovine serum (FBS) from Hyclone (Jarrard et al., 1999) . Growth inhibition was determined at day 6 posttransduction of AdRSVp16 at moi=200. Senescence status was determined by senescence-associated b-galactosidase staining at day 6 after AdRSVp16 transduction Cells were synchronized by serum starvation in 0.5% FBS at 378C for 48 h. The synchronized cells were replated in the medium containing 10% FBS to reentering the cell cycle at 378C for 16 h, then the cells were either untreated or treated with viral transduction (day 0). Cells were harvested at dierent time points before (day 0) and after viral transduction (day 2 and 4 posttransduction) and cellular DNA contents that represented the cell cycle phase (G 0 /G 1 , S, or G 2 /M) were detected by¯ow cytometry via determination of propridium iodide as described in Materials and methods Laboratories (Logan, UT, USA). Human embryonic kidney 293 cells were grown in D-MEM with 10% heat inactivated FBS. Human prostate cancer cell lines PPC-1, PC-3, TSU-Pr, LNCaP, DU145, DUC-1 and DUC-2 were grown in RPMI-1640 medium with 10% FBS. All cell lines were mycoplams negative. All cells were grown in medium containing 100 units/ ml penicillin and 100 mg/ml streptomycin at 378C in 5% CO 2 .
Generation of recombinant adenovirus AdRSVp16
A detailed construction of adenovirus expressing wild-type p16 was described before . Brie¯y, a 965-bp p16 cDNA gene was placed in adenoviral shuttle vector under the control of a truncated RSV promoter. The resultant adenoviral shuttle vector was cotransfected into 293 cells with pJM17, an adenoviral genome plasmid, by calcium phosphate method. The individual plaques were screened by direct PCR method (Lu et al., 1998a) using speci®c primers for the RSV promoter and the p16 gene. The control virus AdRSV2C9 which is an adenovirus carrying an unrelated gene was generated in a similar way.
Adenoviral preparation and transduction
All the procedures were previously described (Lu et al., 1999; Zhang et al., 1999a) . Individual clone of recombinant AdRSVp16 was a gift from Genotherapeutics, Inc., Memphis, TN, USA. A single viral clone was propagated in 293 cells. The culture medium of the 293 cells exhibiting a cytopathic eect was collected for adenovirus puri®cation. The adenovirus was concentrated by twice CsCl 2 gradient ultracentrifugation. Viral titer was determined by plaque assays in 293 cells (Graham and Prevec, 1991) . The recombinant adenovirus assay (RCA) of AdRSVp16 tested negative. Adenoviral transduction of cell lines was performed by addition of the viral solutions at various moi to cell monolayers which were incubated at 378C for 3 h with brief agitation every 15 min during the ®rst 90-min incubation. After 3 h exposure to virus, the viral solution was discarded and fresh medium was added to the cultured cells.
Northern blot
Total RNA was isolated by RNeasy Kit (Qiagen, Santa Clarita, CA, USA). Total RNA was loaded onto a 1.2% polyacrylamide gel. Following electrophoresis, the gel was blotted onto a nylon membrane (Hybond-N + , Amersham Life Science, Buckinghamshire, England) was routinely performed as previously described (Lu et al., 1998b) . The cDNA probe of p16 was labeled by a-32 P-dCTP using random primer method (Prime-It II Kit, Stratagene, La Jolla, CA, USA). The membrane was hybridized with the p16 cDNA probe in Rapid-hyb buer (Amersham Life Science, Piscataway, NJ, USA) according to the manufacturer's protocol. The membrane was exposed to a Kodak X-ray ®lm between two intensifying screens at 7808C for autoradiography. b-actin cDNA probe was labeled as described above and used as an internal control for normalization.
Growth inhibition assay
Cells were plated at a density of 5610 3 cells per well in 6-well plates. After 24 h, cells were either incubated in 1 mM 5-azadeoxycytosine at 378C or transduced by AdRSVp16. The cell numbers were determined using a Coulter cell counter (in duplicate) at indicated days after viral infection.
Reverse-transcriptase polymerase chain reaction (RT ± PCR)
The total RNA was isolated from cells using RNeasy Total RNA Kit (Qiagen) according to the manufacturer's protocol.
After treatment of total RNA with RNase-free DNase I (Gibco ± BRL), reverse transcriptase reaction was carried out using Superscript II RT (Gibco ± BRL) according to the manufacturer's protocol. An aliquot of the RT mixture was subsequently used for the PCR reaction. The primers were 5'-AGAAGCCATTGAAATCTACCTC-3' and 5'-TTCGAG-GAATGTGAGGTATTGG-3', which were speci®c to Rb gene nucleotide positions 2054 to 2490 (Lee et al., 1987) and which resulted in a 332 bp RT ± PCR product for DU145 cells and both a 332 bp and a 437 bp RT ± PCR products for DUC-1 and DUC-2 cells. PCR was performed in 50-ml total volume containing 5 ± 10 ml above RT mixture, in a ®nal concentration of 4 mM MgCl 2 , 50 mM KCl, 0.2 mM each of dNTPs, 20 mM Tris-HCl (pH 8.4), 2 mM each of the primers, and 2.5 units of Taq DNA polymerase (Gibco ± BRL). The reaction was carried out at 948C for 4 min; then for 30 cycles at 948C for 1 min, 608C for 2 min, and 728C for 2 min; followed by at 728C for 10 min. To ensure the quality of total RNA samples, the same RT mixture mentioned above was used for PCR of housekeeper gene b-actin. The primers speci®c to b-actin gene were 5'-TCCTGTGGCATCCAC-GAAACT-3' and 5'-GAAGCATTTGCGGTGGACGAT-3' which resulted a 314 bp PCR product (Steiner et al., 1999b) . Same conditions for PCR described above were used for PCR of b-actin except the reaction was carried out at 948C for 4 min; then for 30 cycles at 948C for 1 min, 558C for 1 min, and 728C for 1 min; followed by at 728C for 10 min.
Western blot
Cells were extracted and processed for gel electrophoresis as previously described (Lu et al., 1995) . Cell extract lysates (100 mg) were loaded on polyacrylamide gels and subjected to sodium dodecylsulfate (SDS) gel electrophoresis, then transferred to a nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA, USA). The membrane was treated with blocking solution (15% nonfat milk, 0.02% sodium azide in phosphate-buered saline) overnight at 48C. The membrane was incubated for 1 h at room temperature with the primary antibody mouse anti-human Rb antibody from PharMingen (San Diego, CA, USA). The membrane was then incubated for 1 h at room temperature with goat anti-mouse secondary antibody coupled to peroxidase (ECL Kit, Amersham Life Science), and performed ECL according to the manufacturer's protocol.
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I-labeled second antibody (Amersham Life Science) was also used instead of peroxidase-coupled secondary antibody.
X-gal staining for senescence-associated b-galactosidase Cells were ®xed in 10 mM NaH 2 PO 4 , 150 mM NaCl, 1 mM MgCl 2 , and 1% glutaraldehyde at 378C for 45 min, and plates were rinsed with PBS three times, and were incubated at 378C for overnight in substrate solution of 1 mg/ml X-gal, 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 150 mM NaCl, 1 mM MgCl 2 , 40 mM citric acid, and 40 mM NaH 2 PO 4 , pH 6.0.
p16 immunohistochemistry
The cells were grown on Slide Flask (Nalge Nunc, Naperville, IL, USA). Day 3 or day 6 after AdRSVp16 transduction, the cells were ®xed in 4% paraformaldehyde. The cells were ®rst incubated with 1% H 2 O 2 for 30 min. The slides were incubated with anti-p16 antibody (Cat# SC-759, dilution 1 : 300, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) for 16 h at 48C, then by secondary antibody and Universal Elite ABC Kit (Vector Laboratories, Inc., Burlingame, CA, USA) according to the manufacturer's protocol. The reaction was visualized with DAB solution (75 mg 3,3'-Diaminobenzidine and 30 ml 50% H 2 O 2 in 150 ml PBS) for 3 ± 10 min. 
